Novel treatment effective against overactive bladder in phase 2 study

Sumary of Novel treatment effective against overactive bladder in phase 2 study:

  • September 10, 2021 2 min read Source/Disclosures Source: Son HS. MP02-18: Efficacy and Safety of DA8010, a novel M3 antagonist, in Patients with Overactive Bladder: Randomized, Double-blind, Phase 2 study.
  • Back to Healio The novel muscarinic M3 receptor antagonist DA8010 significantly reduced urine frequency and urgency episodes compared with placebo in adults with overactive bladder, according to recent findings.
  • Hee Seo Son, MD, PhD, of Yonsei University College of Medicine in South Korea, presented the study data at the virtual American Urological Association meeting.
  • A novel treatment for overactive bladder was effective in a phase 2 trial, according to researchers.
  • The researchers randomly assigned patients to receive one of four treatments: 2.5 mg of DA8010;
  • The researchers evaluated DA8010 for its clinical efficacy, safety and optimal dosage.
  • At 12 weeks, the mean values for 24-hour frequency were -1.01 in the placebo group, -1.22 in the DA8010 2.5-mg group, -1.56 in the solifenacin succinate group and -1.67 in the DA8010 5-mg group.
  • The difference in mean frequency was insignificant in the DA8010 groups compared with the solifenacin succinate group.

Want to know more click here go to source.

From -


Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.